The promise of TRAIL—potential and risks of a novel anticancer therapy
暂无分享,去创建一个
[1] A. Grandien,et al. High level of cFLIP correlates with resistance to death receptor-induced apoptosis in bladder carcinoma cells. , 2003, Anticancer research.
[2] B. Sipos,et al. TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma , 2006, Oncogene.
[3] A. Evdokiou,et al. Human osteoblasts are resistant to Apo2L/TRAIL-mediated apoptosis. , 2002, Bone.
[4] G. Cohen,et al. Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1 , 2005, Cell Death and Differentiation.
[5] C. Ware,et al. Enhanced Apoptosis and Tumor Regression Induced by a Direct Agonist Antibody to Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Receptor 2 , 2005, Clinical Cancer Research.
[6] M. Gregor,et al. HDAC inhibitor treatment of hepatoma cells induces both TRAIL‐independent apoptosis and restoration of sensitivity to TRAIL , 2006, Hepatology.
[7] B. Nickoloff,et al. Pathways involved in proliferating, senescent and immortalized keratinocyte cell death mediated by two different TRAIL preparations , 2002, Experimental dermatology.
[8] G. Gores,et al. Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells. , 2006, American journal of physiology. Gastrointestinal and liver physiology.
[9] P. Richardson,et al. TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. , 2001, Blood.
[10] Lifen Gao,et al. Hepatitis B Virus Sensitizes Hepatocytes to TRAIL-Induced Apoptosis through Bax1 , 2007, The Journal of Immunology.
[11] D. Schrump,et al. The Essential Role of the Mitochondria‐Dependent Death‐Signaling Cascade in Chemotherapy‐Induced Potentiation of Apo2L/TRAIL Cytotoxicity in Cultured Thoracic Cancer Cells: Amplified Caspase 8 Is Indispensable for Combination‐Mediated Massive Cell Death , 2006, Cancer journal.
[12] E. Bröcker,et al. Proteasome Inhibition Results in TRAIL Sensitization of Primary Keratinocytes by Removing the Resistance-Mediating Block of Effector Caspase Maturation , 2003, Molecular and Cellular Biology.
[13] B. Kroesen,et al. Simultaneous Inhibition of Epidermal Growth Factor Receptor (EGFR) Signaling and Enhanced Activation of Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Receptor-mediated Apoptosis Induction by an scFv:sTRAIL Fusion Protein with Specificity for Human EGFR* , 2005, Journal of Biological Chemistry.
[14] A. Kraft,et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) triggers apoptosis in normal prostate epithelial cells , 2002, Oncogene.
[15] H. Xin,et al. Enhanced killing of melanoma cells by simultaneously targeting Mcl-1 and NOXA. , 2006, Cancer research.
[16] T. Burns,et al. The caspase 9 inhibitor Z-LEHD-FMK protects human liver cells while permitting death of cancer cells exposed to tumor necrosis factor-related apoptosis-inducing ligand. , 2000, Cancer research.
[17] A. Teufel,et al. Histone deacetylase inhibition by valproic acid down-regulates c-FLIP/CASH and sensitizes hepatoma cells towards CD95- and TRAIL receptor-mediated apoptosis and chemotherapy. , 2006, Oncology reports.
[18] E. D. de Vries,et al. The clinical trail of TRAIL. , 2006, European journal of cancer.
[19] S. Marsters,et al. Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family* , 1996, The Journal of Biological Chemistry.
[20] H. Walczak,et al. Target cell‐restricted and ‐enhanced apoptosis induction by a scFv:sTRAIL fusion protein with specificity for the pancarcinoma‐associated antigen EGP2 , 2004, International journal of cancer.
[21] M. Smyth,et al. TRAIL and its receptors as targets for cancer therapy , 2004, Cancer science.
[22] Wafik S El-Deiry,et al. Defining characteristics of Types I and II apoptotic cells in response to TRAIL. , 2002, Neoplasia.
[23] M. Andreeff,et al. Activity of TNF‐related apoptosis‐inducing ligand (TRAIL) in haematological malignancies , 1997, British journal of haematology.
[24] N. Hou,et al. Blockade of TRAIL pathway ameliorates HBV-induced hepatocyte apoptosis in an acute hepatitis model. , 2007, Biochemical and biophysical research communications.
[25] P. Scheurich,et al. TNF-related apoptosis inducing ligand (TRAIL) and its receptors in tumor surveillance and cancer therapy , 2002, Apoptosis.
[26] Andreas Untergasser,et al. Preclinical Differentiation between Apparently Safe and Potentially Hepatotoxic Applications of TRAIL Either Alone or in Combination with Chemotherapeutic Drugs , 2006, Clinical Cancer Research.
[27] J. Jelinek,et al. TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors , 2002, Leukemia.
[28] B. Kroesen,et al. Exceptionally potent anti-tumor bystander activity of an scFv:sTRAIL fusion protein with specificity for EGP2 toward target antigen-negative tumor cells. , 2004, Neoplasia.
[29] Z. Wang,et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity , 2001, Nature Medicine.
[30] P. Smolewski,et al. The inhibitor of apoptosis protein family and its antagonists in acute leukemias , 2004, Apoptosis.
[31] C A Smith,et al. Identification and characterization of a new member of the TNF family that induces apoptosis. , 1995, Immunity.
[32] S. Inoue,et al. Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies , 2004, Cell Death and Differentiation.
[33] K. Totpal,et al. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. , 2001, The Journal of pharmacology and experimental therapeutics.
[34] P. Secchiero,et al. TNF-related apoptosis-inducing ligand (TRAIL): a potential candidate for combined treatment of hematological malignancies. , 2004, Current pharmaceutical design.
[35] M. Smyth,et al. Increased Susceptibility to Tumor Initiation and Metastasis in TNF-Related Apoptosis-Inducing Ligand-Deficient Mice1 , 2002, The Journal of Immunology.
[36] A. Evdokiou,et al. Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to apo2l/trail‐induced apoptosis , 2002, International journal of cancer.
[37] E. Bröcker,et al. Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes. , 2000, Cancer research.
[38] P. Marks,et al. Histone deacetylase inhibitors: discovery and development as anticancer agents , 2005, Expert opinion on investigational drugs.
[39] G. Cohen,et al. Upregulation of TRAIL-R2 is not involved in HDACi mediated sensitization to TRAIL-induced apoptosis , 2006, Cell Death and Differentiation.
[40] A. Österborg,et al. Sensitization to TRAIL-induced apoptosis and modulation of FLICE-inhibitory protein in B chronic lymphocytic leukemia by actinomycin D , 2001, Leukemia.
[41] P. Hersey,et al. Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types , 2000, FEBS letters.
[42] U. Jaeger,et al. Expression of tumour necrosis factor (TNF)‐related apoptosis‐inducing ligand (TRAIL) receptors and sensitivity to TRAIL‐induced apoptosis in primary B‐cell acute lymphoblastic leukaemia cells , 2000, British journal of haematology.
[43] T. Sayers,et al. Induction of Tumor-specific T Cell Immunity by Anti-DR5 Antibody Therapy , 2004, The Journal of experimental medicine.
[44] T. Sayers,et al. Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis is an important endogenous mechanism for resistance to liver metastases in murine renal cancer. , 2003, Cancer research.
[45] F. Ballet,et al. Isolation, Culture and Characterization of Adult Human Hepatocytes from Surgical Liver Biopsies , 1984, Hepatology.
[46] A. Evdokiou,et al. Enhanced Apoptosis of Soft Tissue Sarcoma Cells with Chemotherapy: A Potential New Approach Using Trail , 2001, Journal of orthopaedic surgery.
[47] I. Ishida,et al. Human normal hepatocytes are susceptible to apoptosis signal mediated by both TRAIL-R1 and TRAIL-R2 , 2004, Cell Death and Differentiation.
[48] J. Hsieh,et al. Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies , 2006, Nature Cell Biology.
[49] H. Hondermarck,et al. Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21(waf1). , 2004, Experimental cell research.
[50] Robin Foà,et al. TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL. , 2005, Haematologica.
[51] William E Grizzle,et al. Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[52] I. Bechmann,et al. Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL) , 2000, The Lancet.
[53] P. Krammer,et al. c-FLIPR, a New Regulator of Death Receptor-induced Apoptosis* , 2005, Journal of Biological Chemistry.
[54] F. Beguinot,et al. Tumor Necrosis Factor-related Apoptosis-inducing Ligand-induced Death-inducing Signaling Complex and Its Modulation by c-FLIP and PED/PEA-15 in Glioma Cells* , 2002, The Journal of Biological Chemistry.
[55] V. Yong,et al. Human Astrocytes Are Resistant to Fas Ligand and Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis , 2006, The Journal of Neuroscience.
[56] P. Möller,et al. TRAIL and its receptors in the colonic epithelium: a putative role in the defense of viral infections. , 2002, Gastroenterology.
[57] Z. Wang,et al. TRAIL-R2 (DR5) Mediates Apoptosis of Synovial Fibroblasts in Rheumatoid Arthritis1 , 2003, The Journal of Immunology.
[58] D. Tyrrell,et al. TRAIL Inhibits Tumor Growth but Is Nontoxic to Human Hepatocytes in Chimeric Mice , 2004, Cancer Research.
[59] C. Trautwein,et al. Involvement of TRAIL and its receptors in viral hepatitis , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[60] Ken Garber,et al. New apoptosis drugs face critical test , 2005, Nature Biotechnology.
[61] B. Nickoloff,et al. Low‐dose UV‐radiation sensitizes keratinocytes to TRAIL‐induced apoptosis , 2004, Journal of cellular physiology.
[62] L. Altucci,et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells , 2005, Nature Medicine.
[63] J. Pober,et al. TRAIL Induces Apoptosis and Inflammatory Gene Expression in Human Endothelial Cells 1 , 2003, The Journal of Immunology.
[64] Y. Rustum,et al. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice. , 2002, Cancer research.
[65] O. Ogawa,et al. TRAIL and chemotherapeutic drugs in cancer therapy. , 2004, Vitamins and hormones.
[66] P. Secchiero,et al. Ionizing radiation sensitizes erythroleukemic cells but not normal erythroblasts to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)--mediated cytotoxicity by selective up-regulation of TRAIL-R1. , 2001, Blood.
[67] A. Thorburn,et al. Death receptor-induced cell killing. , 2004, Cellular signalling.
[68] G. Gores,et al. Activated stellate cells express the TRAIL receptor‐2/death receptor‐5 and undergo TRAIL‐mediated apoptosis , 2003, Hepatology.
[69] M. Berger,et al. mTOR Controls FLIPS Translation and TRAIL Sensitivity in Glioblastoma Multiforme Cells , 2005, Molecular and Cellular Biology.
[70] T. Luger,et al. Interleukin-1 Protects Transformed Keratinocytes from Tumor Necrosis Factor-related Apoptosis-inducing Ligand* , 1998, The Journal of Biological Chemistry.
[71] John Calvin Reed,et al. FLIP protein and TRAIL-induced apoptosis. , 2004, Vitamins and hormones.
[72] S. S. Strom,et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions , 2001, Nature Medicine.
[73] D. Zink,et al. Hepatocyte growth factor induces Mcl‐1 in primary human hepatocytes and inhibits CD95‐mediated apoptosis via Akt , 2004, Hepatology.
[74] M. Li‐Weber,et al. Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL , 2005, Hepatology.
[75] H. Nishiyama,et al. Enhancement of TRAIL/Apo2L‐mediated apoptosis by adriamycin through inducing DR4 and DR5 in renal cell carcinoma cells , 2003, International journal of cancer.
[76] B. Hylander,et al. The anti-tumor effect of Apo2L/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID mice , 2005, Journal of Translational Medicine.
[77] C. Rauch,et al. Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo , 1999, Nature Medicine.
[78] B. Nickoloff,et al. Avoiding premature apoptosis of normal epidermal cells , 2001, Nature Medicine.
[79] H. Wajant,et al. Tumor therapeutics by design: targeting and activation of death receptors. , 2005, Cytokine & growth factor reviews.
[80] N. Müller,et al. A CD40–CD95L fusion protein interferes with CD40L-induced prosurvival signaling and allows membrane CD40L-restricted activation of CD95 , 2006, Journal of Molecular Medicine.
[81] T. Lehnert,et al. Expression of TRAIL and TRAIL receptors in colon carcinoma: TRAIL-R1 is an independent prognostic parameter. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[82] L. Sedger,et al. Characterization of the in vivo function of TNF‐α‐related apoptosis‐inducing ligand, TRAIL/Apo2L, using TRAIL/Apo2L gene‐deficient mice , 2002, European journal of immunology.
[83] G. Cohen,et al. TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies. , 2005, Cancer research.
[84] E. D. de Vries,et al. TRAIL Induces Apoptosis in Human Colorectal Adenoma Cell Lines and Human Colorectal Adenomas , 2006, Clinical Cancer Research.
[85] D. Rimm,et al. Evaluating the Expression and Prognostic Value of TRAIL-R1 and TRAIL-R2 in Breast Cancer , 2005, Clinical Cancer Research.
[86] D. Lawrence,et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. , 1999, The Journal of clinical investigation.
[87] N. Munshi,et al. Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. , 2002, Blood.
[88] M. Manns,et al. Tumour necrosis factor related apoptosis inducing ligand (TRAIL) induces hepatic steatosis in viral hepatitis and after alcohol intake , 2005, Gut.
[89] A. Kolb,et al. TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer‐specific apoptosis within a therapeutic window , 2007, Hepatology.
[90] B. Kroesen,et al. Target cell-restricted apoptosis induction of acute leukemic T cells by a recombinant tumor necrosis factor-related apoptosis-inducing ligand fusion protein with specificity for human CD7. , 2005, Cancer research.
[91] M. Fiscella,et al. HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo , 2005, British Journal of Cancer.
[92] T. Giordano,et al. Inflammatory cytokine regulation of TRAIL-mediated apoptosis in thyroid epithelial cells , 2002, Cell Death and Differentiation.
[93] Is TRAIL hepatotoxic? , 2001, Hepatology.
[94] T. Griffith,et al. Survivin inhibits apoptosis induced by TRAIL, and the ratio between survivin and TRAIL receptors is predictive of recurrent disease in neuroblastoma. , 2006, Journal of pediatric surgery.
[95] T. Sayers,et al. TNF‐related apoptosis‐inducing ligand as a therapeutic agent in autoimmunity and cancer , 2006, Immunology and cell biology.
[96] S. Strom,et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand , 2000, Nature Medicine.
[97] W. Winkelmann,et al. Selective and nonselective toxicity of TRAIL/Apo2L combined with chemotherapy in human bone tumour cells vs. normal human cells , 2003, International journal of cancer.
[98] T. Griffith,et al. Histone deacetylase inhibitors modulate renal cell carcinoma sensitivity to TRAIL/Apo-2L-induced apoptosis by enhancing TRAIL-R2 expression , 2005, Cancer biology & therapy.
[99] M. Smyth,et al. Eradication of established tumors in mice by a combination antibody-based therapy , 2006, Nature Medicine.
[100] P. Schneider,et al. Production of recombinant TRAIL and TRAIL receptor: Fc chimeric proteins. , 2000, Methods in enzymology.
[101] Henning Walczak,et al. The interplay between the Bcl-2 family and death receptor-mediated apoptosis. , 2004, Biochimica et biophysica acta.
[102] Erwin G. Van Meir,et al. Induction and intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) mediated apotosis in human malignant glioma cells. , 2001, Cancer research.
[103] Brian J. Smith,et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. , 2005, Molecular cell.
[104] S. Shankar,et al. HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma , 2005, Oncogene.
[105] I. Bechmann,et al. Tumor-necrosis-factor-related apoptosis-inducing-ligand (TRAIL)-mediated death of neurons in living human brain tissue is inhibited by flupirtine-maleate , 2005, Journal of Neuroimmunology.
[106] H. Koeppen,et al. Isotype-Dependent Inhibition of Tumor Growth In Vivo by Monoclonal Antibodies to Death Receptor 4 , 2001, The Journal of Immunology.
[107] R. Kimberly,et al. Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway , 2003, Oncogene.
[108] T. Shiraishi,et al. Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells , 2004, Oncogene.
[109] T. Griffith,et al. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. , 1998, Journal of immunology.
[110] P. Lu,et al. In vitro efficacy of AdTRAIL gene therapy of bladder cancer is enhanced by trichostatin A-mediated restoration of CAR expression and downregulation of cFLIP and Bcl-XL , 2006, Cancer Gene Therapy.
[111] P. Krammer,et al. The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. , 2000, Experimental cell research.
[112] D. Buchsbaum,et al. TRAIL receptor-targeted therapy. , 2006, Future oncology.
[113] C. Voelkel-Johnson. An Antibody Against DR4 (TRAIL-R1) in Combination with Doxorubicin Selectively Kills Malignant but not Normal Prostate Cells , 2003, Cancer biology & therapy.
[114] Y. Gazitt. TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells , 1999, Leukemia.
[115] Lin Chen,et al. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. , 2005, Genes & development.
[116] J. Schalkwijk,et al. Tumor necrosis factor related apoptosis inducing ligand triggers apoptosis in dividing but not in differentiating human epidermal keratinocytes. , 2003, The Journal of investigative dermatology.
[117] G. Cohen,et al. Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia , 2002, Oncogene.
[118] M L Yarmush,et al. Hepatocytes in collagen sandwich: evidence for transcriptional and translational regulation , 1992, The Journal of cell biology.
[119] C. Smith,et al. Functional analysis of TRAIL receptors using monoclonal antibodies. , 1999, Journal of immunology.
[120] M. Herlyn,et al. Death Induction by Recombinant Native TRAIL and Its Prevention by a Caspase 9 Inhibitor in Primary Human Esophageal Epithelial Cells* , 2004, Journal of Biological Chemistry.
[121] W. El-Deiry,et al. The complementary roles of the extrinsic and intrinsic apoptotic pathways in promoting the death of cancer cells. , 2006, Cancer journal.
[122] T. Sayers,et al. Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy , 2005, Cancer Immunology, Immunotherapy.
[123] A. Ashkenazi,et al. Targeting death receptors in cancer with Apo2L/TRAIL. , 2004, Current opinion in pharmacology.
[124] O. Ogawa,et al. Doxorubicin enhances TRAIL-induced apoptosis in prostate cancer. , 2002, International journal of oncology.
[125] W. Stremmel,et al. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs , 2004, Cell Death and Differentiation.